Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Insulin Resistance Overview 7 Therapeutics Development 8 Pipeline Products for Insulin Resistance - Overview 8 Pipeline Products for Insulin Resistance - Comparative Analysis 9 Insulin Resistance - Therapeutics under Development by Companies 10 Insulin Resistance - Therapeutics under Investigation by Universities/Institutes 11 Insulin Resistance - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Insulin Resistance - Products under Development by Companies 14 Insulin Resistance - Products under Investigation by Universities/Institutes 15 Insulin Resistance - Companies Involved in Therapeutics Development 16 Atara Biotherapeutics, Inc. 16 AUS Bio Limited 17 F. Hoffmann-La Roche Ltd. 18 Gilead Sciences, Inc. 19 GlaxoSmithKline Plc 20 Hadasit Medical Research Services & Development Ltd 21 Sanofi 22 Insulin Resistance - Therapeutics Assessment 23 Assessment by Monotherapy Products 23 Assessment by Target 24 Assessment by Mechanism of Action 26 Assessment by Route of Administration 28 Assessment by Molecule Type 29 Drug Profiles 31 ATA-842 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 Drugs to Inhibit ABHD6 for Gastrointestinal and Metabolic Disorders - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 englerin A - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 FC-98 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 GS-444217 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 L-2286 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 MD-960 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 MD-961 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Peptide for Obesity and Insulin Resistance - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 RG-7992 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 SAR-088 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 Small Molecule for Atherosclerosis and Insulin Resistance - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Small Molecule for Hypertension and Insulin Resistance - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 Small Molecule to Inhibit AMPD2 for Hypertension and Metabolic Disorders - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 SYM-401 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 Synthetic Peptide to Inhibit Protein Kinase C for Type 2 Diabetes and Insulin Resistance - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 Insulin Resistance - Dormant Projects 47 Appendix 48 Methodology 48 Coverage 48 Secondary Research 48 Primary Research 48 Expert Panel Validation 48 Contact Us 48 Disclaimer 49

List of Tables Number of Products under Development for Insulin Resistance, H2 2016 8 Number of Products under Development for Insulin Resistance - Comparative Analysis, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Number of Products under Investigation by Universities/Institutes, H2 2016 11 Comparative Analysis by Clinical Stage Development, H2 2016 12 Comparative Analysis by Early Stage Development, H2 2016 13 Products under Development by Companies, H2 2016 14 Products under Investigation by Universities/Institutes, H2 2016 15 Insulin Resistance - Pipeline by Atara Biotherapeutics, Inc., H2 2016 16 Insulin Resistance - Pipeline by AUS Bio Limited, H2 2016 17 Insulin Resistance - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 18 Insulin Resistance - Pipeline by Gilead Sciences, Inc., H2 2016 19 Insulin Resistance - Pipeline by GlaxoSmithKline Plc, H2 2016 20 Insulin Resistance - Pipeline by Hadasit Medical Research Services & Development Ltd, H2 2016 21 Insulin Resistance - Pipeline by Sanofi, H2 2016 22 Assessment by Monotherapy Products, H2 2016 23 Number of Products by Stage and Target, H2 2016 25 Number of Products by Stage and Mechanism of Action, H2 2016 27 Number of Products by Stage and Route of Administration, H2 2016 28 Number of Products by Stage and Molecule Type, H2 2016 30 Insulin Resistance - Dormant Projects, H2 2016 47 List of Figures Number of Products under Development for Insulin Resistance, H2 2016 8 Number of Products under Development for Insulin Resistance - Comparative Analysis, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Number of Products under Investigation by Universities/Institutes, H2 2016 11 Comparative Analysis by Early Stage Products, H2 2016 13 Assessment by Monotherapy Products, H2 2016 23 Number of Products by Top 10 Targets, H2 2016 24 Number of Products by Stage and Top 10 Targets, H2 2016 24 Number of Products by Top 10 Mechanism of Actions, H2 2016 26 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 26 Number of Products by Molecule Types, H2 2016 29 Number of Products by Stage and Molecule Types, H2 2016 29

Atara Biotherapeutics, Inc. AUS Bio Limited F. Hoffmann-La Roche Ltd. Gilead Sciences, Inc. GlaxoSmithKline Plc Hadasit Medical Research Services & Development Ltd Sanofi